PRODUCT MONOGRAPH

PRESCRIBING INFORMATION CYANOCOBALAMIN INJECTION, …

Supplied: Each ml contains: Cyanocobalamin 1,000 mcg, Sodium Acetate 0.5 mg, Glacial Acetic Acid 0.1 mg, Sodium Chloride 9.0 mg with Benzyl Alcohol 1.5 % as preservative in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH . Multiple dose vials of 10 ml and 30mL.

  Alcohols, Contains, Benzyl, Benzyl alcohol

FLUZONE High-Dose Quadrivalent

sodium chloride solution. - traces of formaldehyde and ovalbumin. ... Quadrivalent does not contain latex (natural rubber). ... (Split Virion)] is a sterile aqueous suspension of inactivated influenza virus for intramuscular injection.

  Solutions, Rubber, Suspension

PRODUCT MONOGRAPH

PRODUCT MONOGRAPH Pr WELLBUTRIN ... incidence in clinical trials with doses of 450 mg/day was approximately 0.39% (2 of 537 subjects). There were no seizures in clinical trials where subjects (n=1638) were treated up to the maximum recommended dose of 300 mg/day. In post marketing data however, seizures have been observed across all doses and

  Product, Monographs, Product monograph

FLUZONE Quadrivalent

Sanofi Pasteur Product Monograph 450/477 - FLUZONE® Quadrivalent Page 4 of 35 FLUZONE® Quadrivalent Influenza Virus Vaccine Quadrivalent Types A and B (Split Virion) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration: Intramuscular injection. Dosage Form/Strength: Suspension for injection.

  Product, Monographs, Product monograph 450, Quadrivalent

PRODUCT MONOGRAPH

PRODUCT MONOGRAPH DUKORAL® Oral, Inactivated Cholera and ETEC Diarrhea Vaccine Oral Suspension Active Immunizing Agent for the Prevention of Diarrhea Caused by Vibrio cholerae and/or heat-labile toxin producing Enterotoxigenic Escherichia coli ATC Code: J07AE01 Manufactured by: Date of Approval: Valneva Sweden AB,

  Product, Monographs, Product monograph

PRODUCT MONOGRAPH INCLUDING PATIENT …

AFLURIA® TETRA (Inactivated Influenza Vaccine (Split Virion)) Product Monograph Page 1 of 24 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION AFLURIA® TETRA Quadrivalent Inactivated Influenza Vaccine (Split Virion) Suspension for Injection Active Immunizing Agent for the Prevention of Influenza ATC Code: J07BB02 2020 - 2021 Strains:

  Information, Product, Patients, Monographs, Medication, Including, Product monograph, Product monograph including patient, Product monograph including patient medication information

doses of 0.3 mL) Active Immunizing Agent Mainz, Rhineland ...

comirnaty (covid-19 vaccine, mrna) product monograph page 2 of 53 recent major label changes 1. indications 11/2021 4. dosage and administration 11/2021 7. warnings and precautions 11/2021 table of contents

PRODUCT MONOGRAPH GRAVOL

Ear/Nose/Throat Dimenhydrinate may mask the presence of underlying organic abnormalities or the toxic effects of certain antibiotics and other drugs, particularly those drugs causing ototoxicity. Endocrine and Metabolism Use with caution in patients who are poor CYP2D6 metabolizers and in patients with thyroid dysfunction. Gastrointestinal

  Nose, Throat

ENGERIX-B

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ENGERIX-B Hepatitis B vaccine (recombinant) 0.5 mL and 1.0 mL suspensions of 20 mcg/mL hepatitis B surface antigen for injection Active immunizing agent against infection caused by all known subtypes of hepatitis B virus ATC Code: J07BC01 GlaxoSmithKline Inc. 7333 Mississauga Road

  Information, Product, Patients, Monographs, Medication, Including, Engerix, Product monograph including patient medication information engerix

FLULAVAL TETRA (2021-2022)

Egg proteins, sodium deoxycholate, ethanol, formaldehyde, sucrose, -tocopheryl hydrogen succinate, polysorbate 80. Thimerosal preservative in the multidose presentation only. For a complete listing see Dosage Forms, Composition and Packaging section. *The prefilled syringe presentation is not available for the 2021- 2 season DESCRIPTION

DEPARTMENT OF HEALTH AND HUMAN SERVICES 200 …

The Executive Order calls for the development of a Health Quality Roadmap that aligns and improves ... cost generic and biosimilar drugs to patients. These efforts would increase competition, reduce drug prices, ... market-based approaches to Medicare reimbursement.

  Development, Market, Biosimilars, The development

EvaluatePharma World Preview 2019, Outlook to 2024

development cost burden • Roche leads the way in biotechnology, with a forecasted $38.7bn of biologic sales in 2024, despite a decrease in biotech market share of -5.4% owing to the effect of biosimilars • Johnson & Johnson are forecast to narrowly overtake Roche to be the biggest spender on pharmaceutical R&D in 2024

  Development, Market, Evaluatepharma

Roche Holdings, Inc. Annual Report 2020

biosimilar erosion as well as market contractions due to COVID-19 particularly for Rituxan, partly compensated by the uptake of new medicines. The Diagnostics Division reported a sales growth of 28% to USD 4.9 billion, due to sales of COVID-19-related tests, notably the cobas SARS-CoV-2 PCR test, which more than offset a decline in routine testing

  Annual, Report, Market, Holdings, 2200, Roche, Biosimilars, 2002 annual report, Roche holdings